Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Short communication: Phenotypic protease inhibitor resistance and cross-resistance in the clinic from 2006 to 2008 and mutational prevalences in HIV from patients with discordant tipranavir and darunavir susceptibility phenotypes.

Bethell R, Scherer J, Witvrouw M, Paquet A, Coakley E, Hall D.

AIDS Res Hum Retroviruses. 2012 Sep;28(9):1019-24. doi: 10.1089/AID.2011.0242. Epub 2012 Mar 23.

PMID:
22098079
2.

Evidence for different susceptibility to tipranavir and darunavir in patients infected with distinct HIV-1 subtypes.

Poveda E, de Mendoza C, Parkin N, Choe S, García-Gasco P, Corral A, Soriano V.

AIDS. 2008 Mar 12;22(5):611-6. doi: 10.1097/QAD.0b013e3282f51eb9.

PMID:
18317002
3.

Changes in darunavir/r resistance score after previous failure to tipranavir/r in HIV-1-infected multidrug-resistant patients.

Spagnuolo V, Gianotti N, Seminari E, Galli L, Fusetti G, Salpietro S, Lazzarin A, Castagna A.

J Acquir Immune Defic Syndr. 2009 Feb 1;50(2):192-5. doi: 10.1097/QAI.0b013e31819367fc.

PMID:
19131889
4.

Emerging HIV-1 resistance to tipranavir and darunavir in patients with virological failure to first-generation protease inhibitors in Taiwan.

Hsieh SM, Chang SY, Hung CC, Sheng WH, Chen MY, Chang SC.

Int J STD AIDS. 2011 Nov;22(11):617-20. doi: 10.1258/ijsa.2009.009007.

PMID:
22096044
5.

Predicting tipranavir and darunavir resistance using genotypic, phenotypic, and virtual phenotypic resistance patterns: an independent cohort analysis of clinical isolates highly resistant to all other protease inhibitors.

Talbot A, Grant P, Taylor J, Baril JG, Liu TF, Charest H, Brenner B, Roger M, Shafer R, Cantin R, Zolopa A.

Antimicrob Agents Chemother. 2010 Jun;54(6):2473-9. doi: 10.1128/AAC.00096-10. Epub 2010 Apr 5.

6.

Pattern and impact of emerging resistance mutations in treatment experienced patients failing darunavir-containing regimen.

Delaugerre C, Pavie J, Palmer P, Ghosn J, Blanche S, Roudiere L, Dominguez S, Mortier E, Molina JM, de Truchis P.

AIDS. 2008 Sep 12;22(14):1809-13. doi: 10.1097/QAD.0b013e328307f24a.

PMID:
18690163
7.

Virologic and immunologic effectiveness of tipranavir/ritonavir (TPV/r)- versus darunavir/ritonavir (DRV/r)-based regimens in clinical practice.

Antoniou T, Raboud JM, Diong C, Su D, Dewhurst N, Buckley V, Kovacs C, Rachlis A, Brunetta J, Smith G, Gough K, Fletcher D, Loutfy MR.

J Int Assoc Physicians AIDS Care (Chic). 2010 Nov-Dec;9(6):382-9. doi: 10.1177/1545109710382041.

PMID:
21138833
8.

Factors associated with the selection of mutations conferring resistance to protease inhibitors (PIs) in PI-experienced patients displaying treatment failure on darunavir.

Lambert-Niclot S, Flandre P, Canestri A, Peytavin G, Blanc C, Agher R, Soulié C, Wirden M, Katlama C, Calvez V, Marcelin AG.

Antimicrob Agents Chemother. 2008 Feb;52(2):491-6. Epub 2007 Nov 26.

9.

Impact of first-line protease inhibitors on predicted resistance to tipranavir in HIV-1-infected patients with virological failure.

Hsieh SM, Chang SY, Hung CC, Sheng WH, Chen MY, Chang SC.

BMC Infect Dis. 2009 Sep 14;9:154. doi: 10.1186/1471-2334-9-154.

10.

Tipranavir: a protease inhibitor from a new class with distinct antiviral activity.

Yeni P.

J Acquir Immune Defic Syndr. 2003 Sep;34 Suppl 1:S91-4. Review.

PMID:
14562864
11.

Natural polymorphisms and unusual mutations in HIV-1 protease with potential antiretroviral resistance: a bioinformatic analysis.

Mata-Munguía C, Escoto-Delgadillo M, Torres-Mendoza B, Flores-Soto M, Vázquez-Torres M, Gálvez-Gastelum F, Viniegra-Osorio A, Castillero-Manzano M, Vázquez-Valls E.

BMC Bioinformatics. 2014 Mar 15;15:72. doi: 10.1186/1471-2105-15-72.

12.
13.

Effectiveness of tipranavir versus darunavir as a salvage therapy in HIV-1 treatment-experienced patients.

Domínguez-Hermosillo JC, Mata-Marin JA, Herrera-González NE, Chávez-García M, Huerta-García G, Nuñez-Rodríguez N, García-Gámez JG, Jiménez-Romero A, Gaytán-Martínez JE.

J Infect Dev Ctries. 2016 Sep 30;10(9):982-987. doi: 10.3855/jidc.6629.

14.

Tipranavir: the first nonpeptidic protease inhibitor for the treatment of protease resistance.

Luna B, Townsend MU.

Clin Ther. 2007 Nov;29(11):2309-18. Review.

PMID:
18158073
15.

Boosted tipranavir versus darunavir in treatment-experienced patients: observational data from the randomized POTENT trial.

Elgadi MM, Piliero PJ.

Drugs R D. 2011 Dec 1;11(4):295-302. doi: 10.2165/11596340-000000000-00000.

16.

HIV-1 protease mutations and protease inhibitor cross-resistance.

Rhee SY, Taylor J, Fessel WJ, Kaufman D, Towner W, Troia P, Ruane P, Hellinger J, Shirvani V, Zolopa A, Shafer RW.

Antimicrob Agents Chemother. 2010 Oct;54(10):4253-61. doi: 10.1128/AAC.00574-10. Epub 2010 Jul 26.

17.

In vitro susceptibility and virological outcome to darunavir and lopinavir are independent of HIV type-1 subtype in treatment-naive patients.

Dierynck I, De Meyer S, Lathouwers E, Vanden Abeele C, Van De Casteele T, Spinosa-Guzman S, de Béthune MP, Picchio G.

Antivir Ther. 2010;15(8):1161-9. doi: 10.3851/IMP1697.

PMID:
21149923
18.

Effect of ritonavir-boosted tipranavir or darunavir on the steady-state pharmacokinetics of elvitegravir.

Mathias AA, Hinkle J, Shen G, Enejosa J, Piliero PJ, Sekar V, Mack R, Tomaka F, Kearney BP.

J Acquir Immune Defic Syndr. 2008 Oct 1;49(2):156-62. doi: 10.1097/QAI.0b013e318183a982.

PMID:
18769354
19.

Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir.

Baxter JD, Schapiro JM, Boucher CA, Kohlbrenner VM, Hall DB, Scherer JR, Mayers DL.

J Virol. 2006 Nov;80(21):10794-801. Epub 2006 Aug 23.

20.

Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples.

Larder BA, Hertogs K, Bloor S, van den Eynde CH, DeCian W, Wang Y, Freimuth WW, Tarpley G.

AIDS. 2000 Sep 8;14(13):1943-8.

PMID:
10997398

Supplemental Content

Support Center